| Company: | Schering-Plough Corporation |
| Ticker Symbol: | NYSE: SGP |
| Class Period: | July 24, 2006 to January 14, 2008 |
| Date Filed: | Jan-24-08 |
| Lead Plaintiff Deadline: | Mar-18-08 |
| Court: | District, NJ |
| Allegations: |
A class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of shareholders who purchased the securities of Schering-Plough Corporation ("Schering-Plough" or the "Company") (NYSE:SGP) between July 24, 2006 and January 14, 2008, inclusive (the "Class Period").
The complaint alleges that the Company and certain of its officers and directors failed to disclose and misrepresented material adverse facts known to defendants or recklessly disregarded by them, thereby artificially inflating the value of Schering-Plough shares during the Class Period. Specifically, the complaint alleges that, during the Class Period, the Company and the other defendants misled investors regarding the increased efficacy of Vytorin, a combination of Zetia and Zocor, over the cheaper generic form of Zocor alone, and delayed disclosing test results demonstrating that Vytorin was not more effective than generic Zocor.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
The complaint alleges that the Company and certain of its officers and directors failed to disclose and misrepresented material adverse facts known to defendants or recklessly disregarded by them, thereby artificially inflating the value of Schering-Plough shares during the Class Period. Specifically, the complaint alleges that, during the Class Period, the Company and the other defendants misled investors regarding the increased efficacy of Vytorin, a combination of Zetia and Zocor, over the cheaper generic form of Zocor alone, and delayed disclosing test results demonstrating that Vytorin was not more effective than generic Zocor.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
